|
?:abstract
|
-
INTRODUCTION: Lopinavir/ritonavir (LPV/r) has been proposed as repurposed drugs for pre-exposure and postexposure prophylaxis as well as therapy of COVID-19 Coronavirus postexposure prophylaxis (COPEP) trial aims at assessing their efficacy as postexposure ring-prophylaxis among adults exposed to SARS-CoV-2 METHODS AND ANALYSIS: COPEP is a two-arm open-label cluster-randomised trial conducted in three cantons of Switzerland Asymptomatic contacts (≥16 years) of individuals diagnosed with COVID-19 will be randomised (2:1) to either LPV/r (400 mg/100 mg two times per day) for 5 days, or a standard of care arm (no treatment) Asymptomatic individuals may be either SARS-CoV-2 positive or negative Contacts living in the single household will form a cluster and will be randomised into the same arm All participants will be followed-up for 21 days and undergo daily monitoring for COVID-19 symptoms The primary endpoint is 21-day incidence of laboratory-confirmed COVID-19 with ≥1 compatible symptom, analysed in an intention-to-treat (ITT) analysis The secondary endpoints include the 21-day incidence of COVID-19 as well as SARS-CoV-2 infection in a modified ITT analysis, excluding participants who had a positive SARS-CoV-2 RT-PCR from oropharyngeal swab and/or a positive SARS-CoV-2 IgG serology at baseline Assuming a 21-day incidence for COVID-19 of 20% among contacts without postexposure chemoprophylaxis, to detect a relative risk reduction of 60% (ie, translating in an absolute reduction from 20% to 8%), with a power of 80%, an alpha of 5% Accounting for design effect of cluster design of circa 1 1, we plan to enrol 200 participants to the LPV/r arm and 100 to the standard of care arm, 300 participants in total ETHICS AND DISSEMINATION: Ethics approval has been granted by the Commission Cantonale d\'Ethique de la Recherche, Ethikkommission Nordwest- und Zentralschweiz and Comitato Etico Cantonale (ref 2020-00864) and Swissmedic (2020DR3056) Results from this trial will be disseminated via journal articles and presentations at national and international conferences TRIAL REGISTRATION NUMBER: Clinicaltrials gov Registry (NCT04364022);Swiss National Clinical Trial Portal Registry (SNCTP 000003732) REGISTERED REPORT IDENTIFIER: CCER 2020-0864
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}